Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07436793 · ClinicalTrials.gov registry record · Phase 2
Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT07436793 is a Phase 2 study that is actively recruiting participants, run by New Mexico Cancer Research Alliance. The registered enrollment target is 140 participants.
The verdict
NCT07436793, a Phase 2 study, is actively recruiting participants, sponsored by New Mexico Cancer Research Alliance.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometrial hyperplasia) before surgery. Progestins, similar to the natural hormone progesterone, are approved drugs used in birth control and hormone replacement pills, and some can treat uterine endometrial cancers. In the initial comparison of this rotating umbrella trial, megestrol acetate, a progestin, will be compared to micronized progesterone, a form of natural progesterone that is a hormone produced by body normally. Hormone therapy using megestrol acetate and micronized progesterone may be effective in treating patients with endometrial cancer or atypical endometrial hyperplasia before surgery, and understanding the tissue effects of each agent on the malignant endometrium will uncover novel mechanistic and biomarker data to understand how best to advanced hormone therapy for endometrial cancer.
Interventions
- PROCEDURE Biopsy Procedure
- DRUG Megestrol Acetate
- PROCEDURE Hysterectomy
- PROCEDURE Curettage Procedure
- DRUG Progesterone Only Hormone Replacement Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07436793
The ClinicalTrials.gov registry entry for NCT07436793 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biopsy Procedure is the first listed.
NCT07436793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07436793 about?
NCT07436793 is a clinical study titled "Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial". This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometrial hyperplasia) before surgery. Progestins, similar to the natural hormone progesterone, are approve...
What is the current status of trial NCT07436793?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2026-06-15. Estimated completion is 2031-06-30.
What interventions are being tested in trial NCT07436793?
The interventions under investigation include: Biopsy Procedure (PROCEDURE), Megestrol Acetate (DRUG), Hysterectomy (PROCEDURE), Curettage Procedure (PROCEDURE), Progesterone Only Hormone Replacement Therapy (DRUG).
Who is sponsoring clinical trial NCT07436793?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.